Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis (TaPiOCA)
Frontline Thalidomide for Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide
Sponsor: CW pharmaceutical company
Listed as NCT02966522, this PHASE2 trial focuses on Cardiac Amyloidosis and remains ongoing. Sponsored by CW pharmaceutical company, it has been updated 9 times since 2016, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 4 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
Recruiting PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Nov 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CW pharmaceutical company
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .